Jungla focuses on enhancing clinical genetic and genomic testing through advanced technologies that integrate functional genomics, computational biophysics, and computer science. Their primary offering, the Molecular Evidence Platform (MEP), serves as an active learning engine that systematically generates, evaluates, audits, and distributes evidence models. This platform combines large-scale functional (wet lab) and computational (dry lab) methods to provide a uniform assessment of genetic variants, thereby improving the interpretation of clinical variants. By continuously updating and integrating clinical knowledge, Jungla aims to deliver robust, comprehensive, and clear clinical guidance that addresses the significant gaps in understanding genetic variants.

The MEP is designed to ensure that the clinical evidence it supports is accurate, systematic, auditable, and transparent. Jungla's solutions have demonstrated prospective accuracy that surpasses the recommendations set by leading organizations such as the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP). With a focus on delivering clear metrics of diagnostic value, the platform allows for third-party audits to verify the quality of the evidence provided. By leveraging over 100,000 molecular variants and continuously optimizing their methodologies, Jungla is committed to enhancing the performance and scope of clinical interpretations in genetics.

United States

Jungla's Molecular Evidence Platform (MEP) is an active learning engine that continuously integrates clinical knowledge to systematically generate, evaluate, audit, and distribute evidence models to partners and clients.

Jungla

Company Details